4. U-Strip from Transdermal Specialties

Pennsylvania's Transdermal Specialties has high hopes for its innovative insulin system using its U-Strip platform. The tech is an external patch that uses alternating ultrasonic waves to expand pores, allowing for large-molecule drugs to get through the skin and into the bloodstream non-invasively. Transdermal Specialties unveiled an insulin-delivery application for the platform this month at the American Diabetes Association's convention and is in the midst of clinical trials with hundreds of Type 1 and 2 diabetics. The system is designed to be compatible with smartphone-based glucose monitors, and Transdermal Specialties is planning to get it approved and on the market by 2014.

4. U-Strip from Transdermal Specialties
Read more on

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.